Blood outgrowth endothelial cell-based systemic delivery of antiangiogenic gene therapy for solid tumors

Cancer Gene Therapy

Volumn 17, Issue 12, 2010, Pages 855-863

  Bodempudi, V ^a,b   Ohlfest, J R ^b   Terai, K ^a,b   Zamora, E A ^b   Vogel, R I ^c   Gupta, K ^a,b   Hebbel, R P ^a,b   Dudek, A Z ^a,b  

^a Vascular Biology Center   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

angiostatin endostatin fusion protein; blood outgrowth endothelial cells; sFlt1

Indexed keywords

ANGIOSTATIN; ENDOSTATIN; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC GENE THERAPY; ARTICLE; BLOOD OUTGROWTH ENDOTHELIAL CELL; BREAST TUMOR; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; GENE TARGETING; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG TUMOR; MALE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY VEIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; TRANSGENIC MOUSE; TREATMENT RESPONSE; TUMOR VOLUME;

ANGIOGENESIS INHIBITORS; ANGIOSTATINS; ANIMALS; BLOOD CELLS; CELL LINE, TUMOR; CELLS, CULTURED; ENDOSTATINS; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; PHENOTYPE;

MUS; MUS MUSCULUS;

EID: 78349309041     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2010.42     Document Type: Article

References (21)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
3. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-77.
4. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002; 99: 457-462.
5. Dudek AZ, Bodempudi V, Welsh BW, Jasinski P, Griffin RJ, Milbauer L et al. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer 2007; 97: 513-522.
6. Ohlfest JR, Demorest ZL, Motooka Y, Vengco I, Oh S, Chen E et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005; 12: 778-788.
7. Somani A, Nguyen J, Milbauer LC, Solovey A, Sajja S, Hebbel RP. The establishment of murine blood outgrowth endothelial cells and observations relevant to gene therapy. Transl Res 2007; 150: 30-39.
8. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 1994; 91: 11236-11240.
9. Yoshino H, Ueda T, Kawahata M, Kobayashi K, Ebihara Y, Manabe A et al. Natural killer cell depletion by anti-asialo GM1 antiserum treatment enhances human hematopoietic stem cell engraftment in NOD/Shi-scid mice. Bone Marrow Transplant 2000; 26: 1211-1216.
10. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
11. Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL et al. De novo induction of genetically engineered brain tumors in mice using plasmid DNA. Cancer Res 2009; 69: 431-439.
12. Zhou XH, Gao S. Confidence intervals for the log-normal mean. Stat Med 1997; 16: 783-790.
13. Kaplan EL MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Wei J, Jarmy G, Genuneit J, Debatin KM, Beltinger C. Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy. Gene Ther 2007; 14: 344-356.
15. Ferrari N, Glod J, Lee J, Kobiler D, Fine HA. Bone marrow-derived, endothelial progenitor-like cells as angio-genesis-selective gene-targeting vectors. Gene Ther 2003; 10: 647-656.
16. Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003; 1: 1356-1370.
17. Hristov M, Weber C. Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance. J Cell Mol Med 2004; 8: 498-508.
18. Li X, Tjwa M, Moons L, Fons P, Noel A, Ny A et al. Revascularization of ischemic tissues by PDGF-CC via effects on endothelial cells and their progenitors. J Clin Invest 2005; 115: 118-127.
19. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
20. Wei J, Blum S, Unger M, Jarmy G, Lamparter M, Geishauser A et al. Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery. Cancer Cell 2004; 5: 477-488.
21. Milbauer LC, Enenstein JA, Roney M, Solovey A, Bodempudi V, Nichols TC et al. Blood outgrowth endothe-lial cell migration and trapping in vivo: a window into gene therapy. Transl Res 2009; 153: 179-189.